recombinant fowlpox-b7.1 vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2001 (NCT00030693)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-lymphocyte activation antigen CD80Immunity, active
CD80 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- recombinant fowlpox-b7.1 vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00030693 | Phase 1 | Dec 1, 2001 | Icahn School of Medicine at Mount Sinai, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2001 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2001 |
2 organizations
Page 1 / 1